breast cancer and glp 1 drugs GLP-1 cut risk by 30%? Not so fast Study links GLP-1 drugs to

Bone health monitoring Rapid weight loss from any cause, including GLP-1 therapy, can accelerate bone density loss, particularly in postmenopausal women

Amini et al., 2022)

All dosages of danuglipron significantly reduced patients HbA1c and fasting blood glucose levels, with more pronounced weight loss effects observed in the 80 mg and 120 mg doses compared to the placebo group

One such approach is not to analyse the changing multi-component odour trace compound by compound, but rather holistically, to identify groups of compounds that co-vary in their temporal expression and might be related to a given event or state

But it depended on the dosage and time